Imago BioSciences, Inc. Announces Proposed Initial Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif. – July 12, 2021 – Imago BioSciences, Inc. (“Imago”), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs)

Imago BioSciences’ Bomedemstat Demonstrates Continued Encouraging Clinical Activity in Phase 2 Data for Treatment of Essential Thrombocythemia and Myelofibrosis at EHA 2021 Virtual Congress

SOUTH SAN FRANCISCO, Calif. – June 11, 2021 – Imago BioSciences, Inc. (“Imago”), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today provided updates on two Phase 2 clinical trials

Imago BioSciences Appoints Wan-Jen Hong, M.D., as Chief Medical Officer

SOUTH SAN FRANCISCO, Calif. — June 3, 2021 –(BUSINESS WIRE)– Imago BioSciences, Inc. (“Imago”), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced the appointment of Wan-Jen Hong, M.D., as chief medical officer.

Read More

Imago BioSciences to Present Updated Data from Phase 2 Studies of Bomedemstat for the Treatment of Essential Thrombocythemia and Myelofibrosis at 2021 European Hematology Association Virtual Congress

South San Francisco, CA, May 21, 2021 — Imago BioSciences, Inc. (“Imago”), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced that updated Phase 2 data from its two clinical programs